Virginie Baylot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7809547/publications.pdf

Version: 2024-02-01

16 papers	2,174 citations	687220 13 h-index	996849 15 g-index
17 all docs	17 docs citations	17 times ranked	4724 citing authors

#	Article	IF	Citations
1	MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. ELife, 2020, 9, .	2.8	38
2	The MYC oncogene is a global regulator of the immune response. Blood, 2018, 131, 2007-2015.	0.6	158
3	Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC). Oncotarget, 2018, 9, 5517-5528.	0.8	33
4	Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma. , 2018, 6, 125.		85
5	MYC: Master Regulator of Immune Privilege. Trends in Immunology, 2017, 38, 298-305.	2.9	70
6	Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer. Journal of Controlled Release, 2017, 258, 1-9.	4.8	45
7	TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression. Results and Problems in Cell Differentiation, 2017, 64, 255-261.	0.2	7
8	Salmonella Typhimurium utilizes a T6SS-mediated antibacterial weapon to establish in the host gut. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5044-51.	3.3	268
9	MYC regulates the antitumor immune response through CD47 and PD-L1. Science, 2016, 352, 227-231.	6.0	989
10	The Functional Landscape of Hsp27 Reveals New Cellular Processes such as DNA Repair and Alternative Splicing and Proposes Novel Anticancer Targets. Molecular and Cellular Proteomics, 2014, 13, 3585-3601.	2.5	65
11	TCTP as therapeutic target in cancers. Cancer Treatment Reviews, 2014, 40, 760-769.	3.4	83
12	Hsp27 as a Therapeutic Target in Cancers. Current Drug Targets, 2014, 15, 423-431.	1.0	45
13	Targeting TCTP as a New Therapeutic Strategy in Castration-resistant Prostate Cancer. Molecular Therapy, 2012, 20, 2244-2256.	3.7	71
14	TP53INP1 as new therapeutic target in castrationâ€resistant prostate cancer. Prostate, 2012, 72, 1286-1294.	1.2	10
15	OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death and Disease, 2011, 2, e221-e221.	2.7	87
16	Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene, 2010, 29, 1883-1896.	2.6	120